Michael Burkes Brophy Sells 23,948 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 23,948 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $5,621,553.52. Following the completion of the sale, the chief financial officer directly owned 99,776 shares in the company, valued at $23,421,418.24. This trade represents a 19.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total value of $9,016,424.50.
• On Wednesday, October 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The shares were sold at an average price of $190.64, for a total transaction of $355,924.88.
• On Tuesday, October 28th, Michael Burkes Brophy sold 2,415 shares of Natera stock. The shares were sold at an average price of $191.16, for a total transaction of $461,651.40.
• On Monday, October 27th, Michael Burkes Brophy sold 781 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $150,201.92.
• On Friday, October 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The shares were sold at an average price of $196.77, for a total transaction of $148,561.35.

Natera Stock Down 0.5%

Shares of NTRA opened at $241.58 on Friday. The company has a market capitalization of $33.42 billion, a P/E ratio of -105.49 and a beta of 1.62. The firm has a 50 day moving average of $234.18 and a 200 day moving average of $191.17. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.26) earnings per share. On average, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

NTRA has been the topic of several research analyst reports. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Evercore ISI boosted their price objective on shares of Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Guggenheim raised their target price on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Wells Fargo & Company boosted their target price on shares of Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Finally, Piper Sandler increased their price target on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NTRA. Rakuten Investment Management Inc. purchased a new stake in shares of Natera in the 3rd quarter worth $34,096,000. SWS Partners grew its stake in shares of Natera by 11.8% during the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock valued at $7,572,000 after acquiring an additional 4,980 shares during the period. Vontobel Holding Ltd. boosted its position in shares of Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock worth $1,373,000 after purchasing an additional 5,614 shares during the period. Baird Financial Group Inc. increased its stake in shares of Natera by 277.8% in the second quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock worth $4,498,000 after purchasing an additional 19,576 shares in the last quarter. Finally, Orion Porfolio Solutions LLC raised its position in shares of Natera by 68.8% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock valued at $2,051,000 after purchasing an additional 4,946 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.